On August 31, XTALPI fell 5.07% in regular trading, trading at 7.21 HKD/share, with turnover of approximately 219 million HKD. The decline came amid broad-based selling across the Life Sciences Tools & Services sector, with major peers including WuXi Biologics down 5.23%, GenScript Biotech down 5.60%, and Insilico Medicine down 6.61%.

The pullback follows a period of elevated volatility after XTALPI reported its interim results on August 19, which showed a swing to a net loss of 252 million yuan from a profit of 82.8 million yuan a year earlier. Revenue declined 23.9% to 394 million yuan, primarily due to a high base from a $51 million upfront licensing payment recognized in the prior-year period. The company noted that excluding this factor, underlying revenue grew 73.8% year-over-year. R&D spending surged 66% as the company increased investment in autonomous laboratories, agentic systems, and proprietary drug pipelines.

The broader sector remained under pressure as market participants reassessed valuations across CXO and innovative drug names following recent policy signals on medical insurance reform and procurement adjustments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)